Treata Pharma

Mar. 18, 2025

Treata Pharma Reports Fourth Quarter and Full Year 2024 Results


Mar. 11, 2025

Treata Pharma Schedules Q4 & Fiscal 2024 Earnings Release and Conference Call

Dec. 10, 2024

Treata Pharma Partner Moberg Pharma AB Reports Topline Data in SUF-201 Phase 3 Study

 
Nov. 07, 2024

Treata Pharma Reports Third Quarter 2024 Results

Nov. 04, 2024

Treata Pharma Schedules Q3 2024 Earnings Release and Conference Call

Oct. 08, 2024

Treata Pharma Enhances Leadership Team with Appointment of New Chief Business Officer

Sep. 24, 2024

Treata Pharma to Present & Participate in 1×1 Meetings at the Planet MicroCap Showcase: VANCOUVER 2024 in Association with Small Cap Discoveries on Thursday, September 26, 2024

Sep. 13, 2024

Treata Pharma Partner Moberg Pharma AB Provides Update on KUB-018 Phase 3 Study

Aug. 08, 2024

Treata Pharma Reports Second Quarter 2024 Results

Aug. 01, 2024

Treata Pharma Schedules Q2 2024 Earnings Release and Conference Call

Jul. 29, 2024

Treata Pharma Acquires Profitable Growth Dermatology Products from ParaPRO for US$89.5 Million

Jun. 14, 2024

Treata Pharma Announces Results of Annual and Special Meeting of Shareholders

May. 09, 2024

Treata Pharma Reports First Quarter 2024 Results

May. 03, 2024

Treata Pharma Schedules Q1 2024 Earnings Release and Conference Call

Mar. 14, 2024

 Treata Pharma Reports Fourth Quarter and Full Year 2023 Results

Mar. 08, 2024

Treata Pharma Schedules Q4 2023 Earnings Release and Conference Call

Jan. 29, 2024

Treata Pharma Announces the dividend payments release dates

Nov. 24, 2023

Treata Pharma Announces Change of Auditor

Nov. 15, 2023

Treata Pharma Announces Normal Course Issuer Bid

Nov. 09, 2023

Treata Pharma Reports Strong Sales & Earnings Growth in Q3 2023

Oct. 27, 2023

Treata Pharma Schedules Q3 2023 Earnings Release and Conference Call

Oct. 12, 2023

Treata Pharma Announces Final Results of Substantial Issuer Bid

Oct. 03, 2023

Treata Pharma Provides Reminder of the Upcoming Expiration of its Substantial Issuer Bid

Sep. 05, 2023

Treata Pharma Announces Intention to Commence Substantial Issuer Bid, Aggregate Price up to $6 Million Canadian Dollars

Aug. 10, 2023

Treata Pharma Releases Q2 2023 Results, Announces Launch of Epuris in Mexico

Jul. 28, 2023

Treata Pharma Schedules Q2 2023 Earnings Release and Conference Call

Jul. 05, 2023

Treata Pharma, Moberg Pharma Announces Approval for SUF-201 in the European Union

Jun. 21, 2023

Treata Pharma Announces Results of Annual and Special Meeting of Shareholders

May. 11, 2023

Treata Pharma Reports First Quarter Results, Highlighted by Record Cash Per Share and Strong Financial Flexibility

May. 04, 2023

Treata Pharma Schedules Q1 2023 Earnings Release and Conference Call

Apr. 18, 2023

Treata Pharma to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference

Mar. 16, 2023

Treata Pharma Reports Fourth Quarter and Full Year 2022 Financial Results

Treata Pharma has officially announced the specific date for its upcoming Q4 2022 earnings release, along with the associated conference call that will be available for investors and other interested parties to participate in. The scheduled date for this important and significant event is set for March 10, 2023.
Mar. 01, 2023

Treata Pharma Announces Closing of New US$35 Million Credit Facility shareholders / owners

©2025 Treata Pharma Corporation
All Rights Reserved.

Treata Pharma Corporation
170 University Avenue, Suite 602
Toronto, ON M5H 3B3
Phone: (905) 693-8285